BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 9627590)

  • 21. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
    Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O
    Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative safety and immunogenicity of an acellular versus whole-cell pertussis component of diphtheria-tetanus-pertussis vaccines in Senegalese infants.
    Simondon F; Yam A; Gagnepain JY; Wassilak S; Danve B; Cadoz M
    Eur J Clin Microbiol Infect Dis; 1996 Dec; 15(12):927-32. PubMed ID: 9031875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationships between functional assays and enzyme immunoassays as measurements of responses to acellular and whole-cell pertussis vaccines.
    Meade BD; Lynn F; Reed GF; Mink CM; Romani TA; Deforest A; Deloria MA
    Pediatrics; 1995 Sep; 96(3 Pt 2):595-600. PubMed ID: 7659484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses.
    Cherry JD; Gornbein J; Heininger U; Stehr K
    Vaccine; 1998 Dec; 16(20):1901-6. PubMed ID: 9796041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis.
    Storsaeter J; Hallander HO; Gustafsson L; Olin P
    Vaccine; 1998 Dec; 16(20):1907-16. PubMed ID: 9796042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunologic and epidemiologic experience of vaccination with a monocomponent pertussis toxoid vaccine.
    Taranger J; Trollfors B; Bergfors E; Knutsson N; Lagergård T; Schneerson R; Robbins JB
    Pediatrics; 2001 Dec; 108(6):E115. PubMed ID: 11731642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of infant and preschool pertussis vaccinations on memory B-cell responses in children at 4 years of age.
    Hendrikx LH; de Rond LG; Oztürk K; Veenhoven RH; Sanders EA; Berbers GA; Buisman AM
    Vaccine; 2011 Aug; 29(34):5725-30. PubMed ID: 21669247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection.
    Matheson AJ; Goa KL
    Paediatr Drugs; 2000; 2(2):139-59. PubMed ID: 10937466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determination of circulating antibodies directed to pertussis toxin and of agglutinogens in children vaccinated with either the whole cell or component pertussis vaccine in France, Japan and Senegal.
    Relyveld E; Oato NH; Guérin N; Coursaget P; Huet M; Gupta RK
    Vaccine; 1991 Nov; 9(11):843-50. PubMed ID: 1759508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity of a five-component acellular pertussis vaccine in infants and young children.
    Halperin SA; Barreto L; Friesen B; Meekison W
    Arch Pediatr Adolesc Med; 1994 May; 148(5):495-502. PubMed ID: 7910089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines.
    Meade BD; Deforest A; Edwards KM; Romani TA; Lynn F; O'Brien CH; Swartz CB; Reed GF; Deloria MA
    Pediatrics; 1995 Sep; 96(3 Pt 2):570-5. PubMed ID: 7659478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.
    Trollfors B; Taranger J; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
    Clin Infect Dis; 1999 Mar; 28(3):552-9. PubMed ID: 10194077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines.
    Olin P; Rasmussen F; Gustafsson L; Hallander HO; Heijbel H
    Lancet; 1997 Nov; 350(9091):1569-77. PubMed ID: 9393335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acellular pertussis vaccine composed of genetically inactivated pertussis toxin: safety and immunogenicity in 12- to 24- and 2- to 4-month-old children.
    Podda A; De Luca EC; Titone L; Casadei AM; Cascio A; Peppoloni S; Volpini G; Marsili I; Nencioni L; Rappuoli R
    J Pediatr; 1992 May; 120(5):680-5. PubMed ID: 1578301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Responses to primary and a booster dose of acellular, component, and whole-cell pertussis vaccines initiated at 2 months of age.
    Huang LM; Lee CY; Lin TY; Chen JM; Lee PI; Hsu CY
    Vaccine; 1996 Jun; 14(9):916-22. PubMed ID: 8843635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Whole-cell and acellular pertussis vaccines.
    Wintermeyer SM; Nahata MC; Kyllonen KS
    Ann Pharmacother; 1994; 28(7-8):925-39. PubMed ID: 7949515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine. The Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
    Podda A; De Luca EC; Contu B; Furlan R; Maida A; Moiraghi A; Stramare D; Titone L; Uxa F; Di Pisa F; Peppoloni S
    J Pediatr; 1994 Jun; 124(6):921-6. PubMed ID: 8201477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents.
    Tran Minh NN; He Q; Ramalho A; Kaufhold A; Viljanen MK; Arvilommi H; Mertsola J
    Pediatrics; 1999 Dec; 104(6):e70. PubMed ID: 10586004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acellular pertussis vaccine as a booster dose for seventeen- to nineteen-month-old children immunized with either whole cell or acellular pertussis vaccine at two, four and six months of age.
    Halperin SA; Mills E; Barreto L; Pim C; Eastwood BJ
    Pediatr Infect Dis J; 1995 Sep; 14(9):792-7. PubMed ID: 8559630
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids.
    Englund JA; Anderson EL; Reed GF; Decker MD; Edwards KM; Pichichero ME; Steinhoff MC; Rennels MB; Deforest A; Meade BD
    Pediatrics; 1995 Sep; 96(3 Pt 2):580-4. PubMed ID: 7659480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.